Cereno Scientific shares progress update in the Phase II study with drug candidate CS1 in the rare disease PAH
Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced an updated progress report of the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1. The study is proceeding well with currently 16 patients enrolled in the study, 9 patients having received CardioMEMS HF System implantation, 5 patients randomized and in active treatment, and 2 patients having completed the study. Recruitment of the 30 PAH patients to be included in the study is on track and top-line results are anticipated at